Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics disclosed that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared beneficial ownership of 934,429 shares of common stock, representing 5.0% of the class.
The holdings are reported under a joint filing agreement dated 02/23/2026; voting and dispositive power are shown as shared among the filers.
OrbiMed Advisors LLC filed an amended Schedule 13G stating beneficial ownership of 1,187,300 shares of Avalo Therapeutics common stock, representing 6.4% of the class as of December 31, 2025.
OrbiMed reports zero sole voting or dispositive power and shared voting and dispositive power over all 1,187,300 shares, held on behalf of other persons entitled to dividends or sale proceeds. The firm certifies the position was not acquired to change or influence control of Avalo Therapeutics.
Avalo Therapeutics, Inc. received an updated ownership report from Caligan Partners LP and David Johnson. They report beneficial ownership of 881,533 shares of Avalo common stock, representing 4.9% of the outstanding shares, based on 18,133,968 shares outstanding as of November 3, 2025.
The shares are held through Caligan-managed funds and accounts, with shared voting and dispositive power over all reported shares. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Avalo Therapeutics.
Point72 Asset Management and related entities report beneficial ownership of 627,502 shares of Avalo Therapeutics common stock, representing 3.5% of the class as of December 31, 2025. The stake is held through an investment fund managed by Point72, with no shares owned directly by the reporting persons.
Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen each report shared voting and dispositive power over these shares and no sole voting or dispositive power. They certify the investment is not for the purpose of changing or influencing control of Avalo Therapeutics.
Avalo Therapeutics, Inc. reported that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and principals Peter Kolchinsky and Rajeev Shah collectively beneficially owned 1,939,065 shares of common stock as of December 31, 2025, representing 9.99% of the company’s common shares.
The position consists of 662,968 common shares and Series C preferred stock convertible into additional common shares, but a 9.99% Beneficial Ownership Blocker limits how much preferred stock can be converted so their beneficial ownership does not exceed this threshold. The group classifies itself as a passive holder, certifying the securities are not held to change or influence control of Avalo Therapeutics.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 887,274 shares of Avalo Therapeutics common stock, equal to 4.8% of the class. They state they previously exceeded 5% ownership on February 10, 2026, but held 5% or less by the filing date and certify the position is not for changing or influencing control of Avalo Therapeutics.
Avalo Therapeutics, Inc. received an amended Schedule 13G from Biotechnology Value Fund and affiliated entities reporting significant ownership of its common stock. As of the close of business on December 31, 2025, the BVF group and a managed account beneficially owned an aggregate of 1,904,257 shares of Avalo common stock, or approximately 9.99% of the outstanding shares.
The position is held through several investment vehicles and includes shares issuable from Series C Non-Voting Convertible Preferred Stock, which is subject to a 9.99% beneficial ownership cap that limits how much can be converted at any time. Avalo had 18,512,757 common shares outstanding as of December 31, 2025, and the reporting holders certify the securities are not held for the purpose of changing or influencing control of the company.
Avalo Therapeutics Inc. shareholder group associated with Balyasny Asset Management reported beneficial ownership of 439,312 shares of common stock, representing about 2.42% of the outstanding class. The shares are held directly by Atlas Diversified Master Fund, Ltd., for which Balyasny Asset Management acts as investment manager.
The filing is an amended Schedule 13G, indicating the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Avalo Therapeutics. Multiple affiliated Delaware entities and Dmitry Balyasny are each reported as having sole voting and dispositive power over the same 439,312 shares.
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander report beneficial ownership of 906,762 shares of Avalo Therapeutics, Inc. common stock, representing 4.9% of the class. They hold shared voting and dispositive power over these shares and no sole power.
The filing notes they briefly owned more than 5% of Avalo’s outstanding common stock on February 3, 2026, but were below the 5% threshold by the date of this statement. The reporting persons state the shares were not acquired to change or influence control of Avalo.
SilverArc Capital Management, LLC and Devesh Gandhi have filed a Schedule 13G reporting a passive ownership stake in Avalo Therapeutics, Inc. Class A common stock. As of the event date, they beneficially own 524,436 shares, representing 2.83% of the outstanding Class A common stock.
All 524,436 shares are reported with shared voting and shared dispositive power, and neither SilverArc nor Gandhi has sole voting or dispositive power over any shares. They certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Avalo Therapeutics.